Compare Enveric Biosciences Inc (ENVB) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Petróleo Brasileiro SA — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Petróleo Brasileiro SA trades at $17.78 (market cap $108.05B). The key difference: Petróleo Brasileiro SA is far larger — about 20310.2× Enveric Biosciences Inc's market cap, and Petróleo Brasileiro SA pays a 9.87% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PBR | |
|---|---|---|
Market Cap | $5.32M | $108.05B |
Sector | Health | Technology |
52-Week High | $17.40 | $22.03 |
52-Week Low | $1.28 | $11.54 |
Enterprise Value | $408.82K | $170.59B |
Dividend Yield | — | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Petrobras (PBR) trades at $17.78, down 0.78% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 5.69, net income margin of 21.47%, and robust cash flow generation of $197.51B from operations in 2025. Recent developments include strategic acquisitions in Africa and renewable energy investments, while Q1 2026 earnings missed expectations but Q3 and Q4 2025 results beat estimates.
PBR presents compelling value with attractive valuation metrics and strong profitability, supported by analyst consensus of $23.90 price target (34% upside). Key risks include oil price volatility and regulatory pressures in Brazil. The company's dividend payments and strategic expansion into renewable fuels provide additional investor appeal amid ongoing operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
